Evaluation of 68Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1
Eur J Nucl Med Mol Imaging. 2016-01-28; 43(7): 1258-1266
DOI: 10.1007/s00259-016-3319-3
Lire sur PubMed
1. Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1258-66. doi:
10.1007/s00259-016-3319-3. Epub 2016 Jan 28.
Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic
neuroendocrine tumors in patients with MEN1.
Morgat C(1)(2)(3), Vélayoudom-Céphise FL(4), Schwartz P(5), Guyot M(5), Gaye
D(6), Vimont D(7)(8), Schulz J(7)(8), Mazère J(7)(8)(5), Nunes ML(4), Smith D(9),
Hindié E(7)(8)(5), Fernandez P(7)(8)(5), Tabarin A(4).
Author information:
(1)CNRS, INCIA, UMR 5287, 33000, Bordeaux, France.
.
(2)University of Bordeaux, INCIA, UMR 5287, 33000, Bordeaux, France.
.
(3)Department of Nuclear Medicine, University Hospital of Bordeaux, 33000,
Bordeaux, France. .
(4)Department of Endocrinology, USN Haut-Lévêque, 33604, Pessac, France.
(5)Department of Nuclear Medicine, University Hospital of Bordeaux, 33000,
Bordeaux, France.
(6)Department of Radiology, University Hospital of Bordeaux, 33604, Pessac,
France.
(7)CNRS, INCIA, UMR 5287, 33000, Bordeaux, France.
(8)University of Bordeaux, INCIA, UMR 5287, 33000, Bordeaux, France.
(9)Department of Oncology, University Hospital of Bordeaux, 33000, Bordeaux,
France.
CONTEXT: Somatostatin receptor scintigraphy with (111)In-pentetreotide (SRS) is
used to detect duodenopancreatic neuroendocrine tumors (dpNETs) in multiple
endocrine neoplasia type 1 (MEN1). However, SRS has limited sensitivity for this
purpose. Positron emission tomography/computed tomography (PET/CT) with
(68)Ga-DOTA-TOC has a higher rate of sporadic dpNETs detection than SRS but there
is little data for dpNETs detection in MEN1.
PURPOSE: To compare the performances of (68)Ga-DOTA-TOC PET/CT, SRS and
contrast-enhanced computed tomography (CE-CT) to diagnose dpNETs in MEN1.
DESIGN AND SETTING: Single-institution prospective comparative study
PATIENTS AND METHODS: Nineteen consecutive MEN1 patients (aged 47 ± 13 years)
underwent (68)Ga-DOTA-TOC PET/CT, SRS, and CE-CT within 2 months in random order.
Blinded readings of images were performed separately by experienced physicians.
Unblinded analysis of CE-CT, combined with additional magnetic resonance imaging,
endoscopic-ultrasound, (18)F-2-fluoro-deoxy-D-glucose ((18)F-FDG) PET/CT or
histopathology results served as reference standard for dpNETs diagnosis.
RESULTS: The sensitivity of (68)Ga-DOTA-TOC PET/CT, SRS, and CE-CT was 76, 20,
and 60 %, respectively (p